Related Experiment Video
Updated: Nov 11, 2025

11:57
Methods to Study Changes in Inherent Protein Aggregation with Age in Caenorhabditis elegans
Published on: November 26, 2017
8.9K
Dissolving the Complex Role Aggregation Plays in Neurodegenerative Disease
Katherine R Croce1, Ai Yamamoto2
1Doctoral Program in Pathobiology, Columbia University, New York, New York, USA.
Summary
The autophagy-linked FYVE protein (Alfy)/Wdfy3 aids in clearing aggregated proteins in the adult brain. Its depletion accelerates neurodegenerative symptoms in a Huntington
Area of Science:
- Neuroscience
- Cell Biology
- Protein Homeostasis
Background:
- Adult-onset neurodegenerative diseases feature misfolded protein accumulation, but their pathogenic role is unclear.
- Maintaining protein homeostasis in the adult central nervous system is complex.
- The autophagy-linked FYVE protein (Alfy)/Wdfy3 is identified as crucial for clearing protein aggregates in the brain.
Purpose of the Study:
- To investigate the role of Alfy/Wdfy3 in the turnover of aggregated proteins in the adult brain.
- To determine the impact of Alfy/Wdfy3 depletion on neurodegenerative disease models.
Main Methods:
- Utilized a mouse model of Huntington's disease.
- Assessed the effects of Alfy depletion on mutant huntingtin protein aggregation and behavioral deficits.
- Examined cell loss in the context of motor dysfunction.
Main Results:
- Alfy depletion accelerated mutant huntingtin protein accumulation and behavioral deficits in the Huntington's disease mouse model.
- Motor dysfunction worsened without increased overt cell loss.
- Protein aggregates appear to modify circuit dysfunction rather than directly cause degeneration.
Conclusions:
- Alfy/Wdfy3 plays a significant role in clearing aggregated proteins in the adult brain.
- Protein aggregates may contribute to neurodegenerative disease pathogenesis by altering neural circuit function.
- Alfy/Wdfy3 could be a target for understanding shared pathogenic events in adult-onset diseases.
Related Concept Videos
Amyloid Fibrils
11.0K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.0K
Amyloid Fibrils
6.1K
6.1K
Alzheimer's Disease: Overview
1.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.0K
Neural Regulation
41.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
41.2K
Alzheimer's Disease: Treatment
539
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
539
Parkinson's Disease: Overview
1.1K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.1K

